Roboearth – Lifestyle
Author:
Skye Bioscience, Inc.
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 12, 2026
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
April 7, 2026
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
April 2, 2026
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 11, 2026